{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.5","upperLimit":"4.8","value":"3.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"PFS was defined as the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. In a clinical trial, measuring the PFS is one way to see how well a new treatment works.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Subjects will receive Pralatrexate 25 mg/m2 and Romidepsin 12 mg/m2 intravenously once weekly on days 1 and 15 on a 28-day cycle.","id":"OG000","title":"Phase II"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Progression Free Survival (PFS) of Subjects in Phase 2","type":"SECONDARY","unitOfMeasure":"months"}